Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
NCT ID: NCT00789763
Last Updated: 2012-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2007-12-31
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase II: Activity profile evaluating Progression-free rates (PFR) at 6 months, Response rate, Overall survival, Toxicity profile
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Definition of maximum tolerated dose (MTD):
The MTD is defined as the highest dose level which can be given to 6 patients such that no more than 1 patient experiences a DLT .
Definition of Recommended Dose (DR):
Is the MTD
Definition of Dose-limiting toxicity (DLT):
DLT will be defined as any of the following occurring during the period of treatment and regarded as related to the combination regimen.
* Grade 4 thrombocytopenia persisting greater than 4 days, or with bleeding requiring platelet transfusion
* Grade 4 neutropenia lasting more than 7 days
* Febrile neutropenia (≥ 38.5oC) with an absolute neutrophil count ≤ 1000/mm3
* Any grade 3 or 4 non-hematologic toxicity related to the combination \[occurring despite optimal supportive care, if applicable\] except hyperglycemia, hypoglycemia, deep venous thrombosis, or hyperbilirubinemia secondary to stent malfunction.
* Hypertension that is symptomatic and not managed by maximal use of three different classes of antihypertensives, or any episode of malignancy hypertension
(Detailed Dose Modifications and G-CSF use in case of febrile neutropenia will be outlined in the full protocol version)
Phase II
Primary objective:
Activity profile evaluating Progression-free rates (PFR) at 6 months
Secondary objective:
Response rate Overall survival Toxicity profile
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sorafenib + gemcitabine + radiotherapy
Gemcitabine
300 mg/m2/one per week, i.v., during 5 weeks.
Radiotherapy
1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
Sorafenib
200-800 mg/day p.o. during 5 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemcitabine
300 mg/m2/one per week, i.v., during 5 weeks.
Radiotherapy
1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
Sorafenib
200-800 mg/day p.o. during 5 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. -Patients with measurable (according to RECIST) disease.
3. -Male or female patients \> or = 18 years old
4. -ECOG 0-1
5. -Adequate bone marrow, liver , and renal function: Absolute neutrophil count ( ANC) \>= 1,500/mm3 Platelets\> or = 100,000/µl Hemoglobin \>=9.0 g/dl Total bilirubin \< 1.5 x the upper limit of normal. ALT and AST \<= 2.5 x upper limit of normal ( \<= 5X upper limit of normal for patients with liver involvement ) Serum creatinine \<= 1.5 times x the upper limit of normal. Patients with creatinine clearance \>= 45mL/min PT( prothrombin time ) or INR( international normalized ratio ) and PTT ( partial thromboplastin time ) \< =1.5 x
6. -Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men should use adequate birth control for at least six months after the last administration of sorafenib
7. -Signed informed consent prior to any study specific procedures
Exclusion Criteria
2. -PTV ( planning target volume ) \>500 cm3 or 5 cm (maximum diameter)
3. -Patients with known or suspected allergy to iodated contrasts or renal impairment which prevents from radiological tests.
4. -Pregnant or nursing patients. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
5. -General medical or psychological conditions that would preclude appropriate informed consent or compliance with the protocol.
6. -Previous cancer that is distinct in primary site or histology from NSCLC except cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis) or any cancer curatively treated \> 3 years prior to study entry
7. -Concurrent treatment with other experimental drugs (within 30 days prior to study entry).
8. -Concurrent treatment with other anti-cancer therapy.
9. -Therapeutic anticoagulation with Vitamin K antagonists such as warfarin or with heparins or heparinoids. Low dose warfarin is permitted if INR is \<1.5 . Low dose aspirin is permitted .
10. -Patients with any medical condition which could jeopardize their safety while his participation in the study .
11. -Significant weight loss (\> or equal 10% body weight during preceding 6 weeks)
12. -Major surgery within 3 previous weeks, or laparoscopic biopsy or significant traumatic injury within 2 weeks of prior to first dose of study drug.
13. -Known or suspected allergy to sorafenib or any agent given in the course of this trial .
14. -Patients with evidence or history of bleeding diathesis or coagulopathy
15. -Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
16. -Uncontrolled hypertension defined as systolic blood pressure \> 150 mm Hg or diastolic pressure \> 90 mm Hg, despite optimal medical management
17. -Cardiac disease: Congestive heart failure \> class II NYHA. Patients must not have unstable angina or new-onset angina (began within the last 3 months) or myocardial infarction within the last 6 months
18. -Patients with Child-Pugh class C hepatic impairment
19. -Patients with severe renal impairment (calculated creatinine clearance of \< 30 ml/min) or who require dialysis
20. -Active clinically serious infections \> CTCAE Grade 2
21. -Serious, non-healing wound, ulcer, or bone fracture
22. -Patients with concomitant ketoconazole, itraconazole,ritonavir,rifampicin or St. John's Wort (Hypericum perforatum).
23. -Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis
24. -Any instable condition that may interfere with the patients participation in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Grupo Espanol Multidisciplinario del Cancer Digestivo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de La Santa Creu I Sant Pau
Barcelona, Barcelona, Spain
Hospital Clinic I Provincial
Barcelona, Barcelona, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Universitario La Fe
Valencia, Valencia, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aparicio J, Garcia-Mora C, Martin M, Petriz ML, Feliu J, Sanchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Espanol Multidisciplinario en Cancer Digestivo (GEMCAD) study. PLoS One. 2014 Jan 9;9(1):e82209. doi: 10.1371/journal.pone.0082209. eCollection 2014.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEMCAD 0701
Identifier Type: -
Identifier Source: org_study_id